MetaCap

Perspective Therapeutics (CATX) vs NRX Pharmaceuticals (NRXP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NRX Pharmaceuticals (NRXP) has outperformed Perspective Therapeutics (CATX) over the past year, gaining 0.9% versus a loss of 63.9%. Over five years, CATX leads with a -84.6% price change compared with -96.8% for NRXP. NRX Pharmaceuticals is the larger company by market cap ($95.3 million vs $91.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CATX-63.93%NRXP+0.94%
+182%+53%-76%
Nov 21, 20251 yearNov 20, 2026
CATX-84.62%NRXP-95.81%
+288%+86%-116%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CATX versus NRXP key metrics
MetricCATXNRXP
Share price$0.7538$2.15
Market cap$91.03M$95.31M
1-day change-3.85%-15.69%
YTD return-72.59%-20.66%
1-year return-63.93%+0.94%
5-year return-84.62%-96.81%
EPS (TTM)$-1.25$-0.33
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.23M
Net income (latest FY)$-103.12M$-28.62M
Gross margin—58.78%
Operating margin—-1324.41%
Net margin—-2336.49%
52-week high$6.16$5.06
52-week low$0.73$1.62
Distance from 52-week high-87.76%-57.47%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1188.14%+1702.33%
Average volume2.70M1.07M
Shares outstanding120.76M44.33M
Employees16329
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NRXP has outperformed CATX by 64.9 percentage points over the past year.

About Perspective Therapeutics

CATX stock →

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.

Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees

About NRX Pharmaceuticals

NRXP stock →

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments.

Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees

CATX vs NRXP FAQ

Which is bigger, Perspective Therapeutics or NRX Pharmaceuticals?

NRX Pharmaceuticals (NRXP) is larger, with a market capitalization of $95.31M compared with $91.03M for Perspective Therapeutics (CATX).

Which stock has performed better over the past year, CATX or NRXP?

NRXP returned +0.94% over the past 12 months, compared with -63.93% for CATX (price return, excluding dividends). Past performance does not predict future results.

Are Perspective Therapeutics and NRX Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons